Azithromycin for mild-to-moderate COVID-19 - Authors' reply
Main Author: | Hinks, TSC |
---|---|
Other Authors: | ATOMIC2 Trial Authors |
Format: | Journal article |
Language: | English |
Published: |
Elseiver
2021
|
Similar Items
-
Azithromycin for mild-to-moderate COVID-19: author's reply
by: Hinks, TSC, et al.
Published: (2021) -
Azithromycin in viral infections
by: Oliver, ME, et al.
Published: (2020) -
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial
by: Hinks, TSC, et al.
Published: (2021) -
A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial
by: Hinks, TSC, et al.
Published: (2021) -
WHO COVID-19 therapeutic guidelines – authors' reply
by: White, NJ, et al.
Published: (2021)